Search

Displaying results 7191 - 7200 of 7460 in total
  1. Drug

    Carbarsone

    go.drugbank.com/drugs/DB11382
    ExperimentalVet approved

    Carbarsone is a compound used as an antiprotozoal drug for the treatment of histomoniasis (or blackhead disease) in addition to other infectious diseases in chicken and turkeys.

  2. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  3. Drug

    3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole

    go.drugbank.com/drugs/DB08727
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. 3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is known to target genome

  4. Drug

    Chromium gluconate

    go.drugbank.com/drugs/DB14528
    Approved

  5. Drug

    Chromium nicotinate

    go.drugbank.com/drugs/DB14529
    Approved

  6. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.

  7. Drug

    Siplizumab

    go.drugbank.com/drugs/DB06371
    Investigational

  8. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  9. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  10. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.